Xtl Biopharmaceuticals Ltd - Statement of Changes in Beneficial Ownership (4)
February 28 2008 - 3:35PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
January 31, 2008
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
EDELMAN JOSEPH
|
2. Issuer Name
and
Ticker or Trading Symbol
XTL BIOPHARMACEUTICALS LTD
[
XTLB
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
__
X
__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
, 499 PARK AVENUE, 25TH FLOOR
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/22/2008
|
(Street)
NEW YORK, NY 10022
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Ordinary Shares
(1)
|
2/22/2008
|
|
P
|
|
444620
|
A
|
$3.95
|
47765130
|
I
|
see footnote
(2)
|
Ordinary Shares
|
2/22/2008
|
|
P
|
|
470000
|
A
|
$3.9458
|
48235130
|
I
|
see footnote
(2)
|
Ordinary Shares
(1)
|
2/22/2008
|
|
P
|
|
188000
|
A
|
$3.9526
|
48432130
|
I
|
see footnote
(2)
|
Ordinary Shares
|
2/25/2008
|
|
P
|
|
728500
|
A
|
$3.8682
|
49151630
|
I
|
see footnote
(2)
|
Ordinary Shares
|
2/25/2008
|
|
P
|
|
94000
|
A
|
$3.8598
|
49245630
|
I
|
see footnote
(2)
|
Ordinary Shares
(1)
|
2/22/2008
|
|
P
|
|
28380
|
A
|
$3.95
|
2469950
|
I
|
see footnote
(3)
|
Ordinary Shares
|
2/22/2008
|
|
P
|
|
30000
|
A
|
$3.9458
|
2499950
|
I
|
see footnote
(3)
|
Ordinary Shares
(1)
|
2/22/2008
|
|
P
|
|
12000
|
A
|
$3.9526
|
2511950
|
I
|
see footnote
(3)
|
Ordinary Shares
(1)
|
2/25/2008
|
|
P
|
|
6000
|
A
|
$3.8598
|
2517950
|
I
|
see footnote
(3)
|
Ordinary Shares
(1)
|
2/25/2008
|
|
P
|
|
46500
|
A
|
$3.8682
|
2564450
|
I
|
see footnote
(3)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
This Form 4 is being filed by Joseph Edelman, Michael Cho, Scott Bradley, Perceptive Life Science Master Fund Ltd. ("Master
Fund") and Perceptive Advisors LLC ("Advisors").
|
(
2)
|
This transaction was effected through the Master Fund. Mr. Edelman is the managing member of Advisors, which in turn serves
as the investment manager of Master Fund. Mr. Edelman and Mr. Bradley share dispositive power over 1,010,000 of such shares
and Mr. Edelman and Mr. Cho share dispositive power of 2,409,350 of such shares. Mr. Edelman has sole voting and dispositive
power over the remainder of such shares. In accordance with Instruction 4(b)(iv) of Form 4, the entire amount of the
Issuer's securities held by Master Fund is reported herein. Each of Mr. Edelman, Mr. Cho, Mr. Bradley and Advisors
disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities,
except to the extent of his/its indirect pecuniary therein, and this report shall not be deemed an admission that Mr.
Edelman, Mr. Cho, Mr. Bradley and Advisors is the beneficial owner of such securities for purposes of Section 16 or for any
other purposes.
|
(
3)
|
This transaction was effected through an account at First New York Trading, LLC. Mr. Edelman and Mr. Cho share dispositive
power over 267,670 of such shares and Mr. Edelman has sole voting and dispositive power over the remainder of such shares.
Mr. Edelman and Mr. Cho each disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial
ownership of such securities, except to the extent of his indirect pecuniary interest therein, and this report shall not be
deemed an admission that Mr. Edelman or Mr. Cho is the beneficial owner of such securities for purposes of Sectioin 16 or
for any other purposes. Mr. "Bradley disclaims beneficial ownership over all such shares.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
EDELMAN JOSEPH
499 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022
|
|
X
|
|
|
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
499 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022
|
|
X
|
|
|
PERCEPTIVE ADVISORS LLC
PERCEPTIVE ADVISORS LLC
499 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022
|
|
X
|
|
|
Cho Michael
MICHAEL CHO
499 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022
|
|
X
|
|
|
Bradley Scott
SCOTT BRADLEY
499 PARK AVENUE, 25TH FLOOR
NEW YORK, NY 10022
|
|
X
|
|
|
Signatures
|
/s/ JOSEPH EDELMAN
|
|
2/27/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Sep 2024 to Oct 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2023 to Oct 2024